Abstract: The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osetoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked ?-gal epitopes for induction of recruitment of macrophages localized within or surrounding damaged tissue. The recruited macrophages recruit stem cells and promote the repair and regeneration of the treated injured tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects. In some embodiments, the present invention provides treatments for injured tissues such as brain, peripheral nerve, heart muscle, skeletal muscle, cartilage, bone, gastrointestinal tract and dysfunctional endocrine tissues.

Abstract: The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osetoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked ?-gal epitopes for induction of an inflammatory response localized within or surrounding damaged tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects.

Abstract: The present invention provides isolated metal regulated polypeptides obtainable from a Campylobacter spp., and compositions including the polypeptides. The present invention also includes methods for using the compositions disclosed herein, including methods for treating in infection in a subject, for treating a condition caused by a Campylobacter spp., and for decreasing colonization of an animal.

Abstract: A CpG DNA adjuvant in avian vaccines is disclosed, which includes an immunostimulatory oligodeoxynucleotide (ODN) having a sequence of SEQ ID NO: 2. The CpG DNA adjuvant in avian vaccines is advantageous to carry out large-scale production, specifically enhance avian innate and adaptive immune responses, and the CpG DNA adjuvant is hardly to be digested by DNase due to its particular structures.

Abstract: The present invention provides an avian recombinant herpesvirus modified by the presence of the cDNA encoding, the VP2 of the Delaware Variant E strain of IBDV, a subtype of IBDV serotype 1 strains. The present invention further provides an avian recombinant herpesvirus comprised of the VP2 gene of which the backbone virus is a Marek's disease vaccine strain, such as herpesvirus of turkeys. A poultry vaccine including the avian herpes recombinant virus described in the present invention can induce in chickens protective immunity against a variety of different subtypes of IBDV.

Abstract: The present invention provides a new antigenic type of chicken anaemia viruses (CAV). The CAV according to this invention is isolatable from turkeys in the field and its virulence for chickens is significantly reduced. This property makes these viruses particularly suited for preparing a live vaccine for protecting poultry against disease conditions resulting from CAV infection.

Abstract: The present invention provides an avian recombinant herpesvirus modified by the presence of the cDNA encoding the VP2 of the Delaware Variant E strain of IBDV, a subtype of IBDV serotype 1 strains. The present invention further provides an avian recombinant herpesvirus comprised of the VP2 gene, of which the backbone virus is a Marek's disease vaccine strain, such as herpesvirus of turkeys. A poultry vaccine including the avian herpes recombinant virus described in the present invention can induce in chickens protective immunity against a variety of different subtypes of IBDV.

Abstract: The present invention provides a new antigenic type of chicken anaemia viruses (CAV). The CAV according to this invention is isolatable from turkeys in the field and its virulence for chickens is significantly reduced. This property makes these viruses particularly suited for preparing a live vaccine for protecting poultry against disease conditions resulting from CAV infection.

Abstract: An immunogenic preparation or vaccine against avian pneumovirosis, comprising an antigen of the avian pneumovirus strain C990427, in a vehicle or excipient which is acceptable from the veterinary point of view and, optionally, an adjuvant.

Abstract: A salmonella live vaccine produced from at least one attenuated immunologic live vaccine strain, characterized in that the vaccine strain has an envelope marker which results in an increased sensitivity of the vaccine strain toward a specific therapeutically effective antibiotic and has at least one chromosomal antibiotic resistance mutation for the attenuation.

Abstract: The present invention is directed to a method to prepare an inactivated w/o emulsion adjuvated vaccine, wherein an aqueous solution comprising one or more inactivated angigens is mixed under mild conditions with a ready-made w/o emulsion. Preferably the vaccine is prepared just prior to vaccination. The aqueous solution and w/o emulsion are stirred or shaken by mechanical means or by hand. The present invention also relates to a kit of parts for use in a method according to the invention.

Abstract: The present invention provides a novel avian herpesvirus (NAHV) vector and recombinant vaccines made therefrom that are useful to immunize avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease. Methods of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease are also provided.

Abstract: The invention encompasses methods and compositions for inducing an immune response in an anti-Gal synthesizing animal including viral and tumor antigens manipulated to express &agr;-galactosyl epitopes.

Abstract: The present invention discloses a DNA molecule that encodes a polypeptide that has the amino acid sequence described in SEQ ID No. 2 or an amino acid sequence that is at least 80% homologous with said amino acid sequence, a recombinant containing said DNA molecule, and a vaccine having for its active ingredient said recombinant.

Abstract: The avian recombinant live vaccine comprises, as vector, an ILTV virus comprising and expressing at least one heterologous nucleotide sequence, this nucleotide sequence being inserted into the insertion locus formed by the intergenic region situated between the stop codons of the ORF D and ORF E of ILTV and which, in a specific ILTV strain, is defined between nucleotides 3873 and 4260 in SEQ ID No:1. The heterologous nucleotide sequence may be under the control of a strong eukaryotic promoter, such as the CMV-IE promoter, and may be derived from the Newcastle disease virus, Marek's disease virus, the infectious bursal disease virus, the infectious bronchitis virus, the chicken anaemia virus and the chicken pneumovirosis virus. Multivalent vaccine formula comprising at least two live vaccines according to the invention. ILTV virus thus recombined.

Abstract: The present invention for the first time discloses a health problem in broilers at about 3-5 weeks, resulting in significant production losses, and demonstrates that these production losses can be prevented by a live attenuated CAA vaccine for mucosal administration.

Abstract: The invention relates to a new aviadenovirus which was isolated from a pigeon. The aviadenovirus according to the present invention comprises group-I specific antigen and cannot be neutralized by antiserum against any of the FAV serotypes 1-12. The present invention also relates to an antibody or antiserum immunoreactive with a fibre of the new aviadenovirus, a fibre thereof as well as a vaccin against PiAV related diseases comprising a chemically or physically inactivated virus an attenuated virus, a fibre or fragment thereof, a host cell transformed with a nucleic acid sequence encoding an amino acid sequence comprising an immunogenic determent or a functional variant thereof of a fibre of the aviadenovirus according to the present invention, together with a pharmaceutical carrier.

Abstract: A system for the generation of live, nonpathogenic Birnavirus such as infectious bursal disease virus (IBDV), a segmented double-stranded (ds)RNA virus of the Birnavirdae family, using synthetic transcripts derived from cloned DNA has been developed. Independent full-length cDNA clones were constructed which contained the coding and non-coding regions of RNA segments A and B of IBDV, respectively. Segment A was modified to prevent the expression of NS protein. Synthetic RNAs of both segments were produced by in vitro transcription of linearized plasmids with T7 RNA polymerase. Transfection of Vero cells with combined plus-sense transcripts of both segments generated infectious virus as early as 36 hours post-transfection. The development of a system for producing NS protein deficient IBDV will greatly facilitate studies of immunosuppression, and aid in the development of live attenuated vaccines for IBDV.

Abstract: The living recombinant avian vaccine comprises, as a vector, an ILTV virus comprising and expressing at least one heterologous nucleotide sequence, this nucleotide sequence being inserted in the insertion locus defined between the nucleotides 1624 and 3606 at the SEQ ID NO: 5. The vaccine may in particular comprise a sequence coding for an antigen of an avian pathogenic agent selected among the group consisting of the Newcastle disease virus (NDV), the infections bursal virus (IBDV), the Marek disease virus (MDV), the infectious bronchitis virus (IBV), the chicken anaemia virus (CAV), thee chicken pneumovirosis virus, preferably under the control of a strong eukariotic promoter. A multivalent vaccine formula is also disclosed.

Abstract: The present invention is concerned with Infectious bursitis virus (IBDV) vaccines containing IBDV antigen material which is derived from a mammalian cell line infected with IBDV.

Abstract: This invention relates to a novel infectious bronchitis virus (IBV) serotype and to attenuated IBV strains derived therefrom, and also to live or inactivated vaccines made using such IB virus. This invention also relates to a method for protecting poultry against IBV using these vaccines.

Abstract: A multivalent poultry vaccine is provided having two or more live biological agents or microbial components. Each live biological agent or microbial component is effective in preventing or treating an avian disease, and the multivalent vaccine is safe and effective for immunizing poultry in ovo. Methods are also provided for vaccinating poultry by administering such a multivalent vaccine in ovo.

Abstract: Methods are provided for improved immunization against coccidiosis and other bacterial, viral, or parasitic diseases in poultry. One method includes administering a solution of Propionibacterium acnes suspended in normal saline to a chick at age day one, following hatching. An anticoccidial vaccine and/or other vaccine is then administered to the chick such as by oral administration. Alternatively the method includes the steps of aseptically injecting Propionibacterium acnes in ovo at about day 18 in development, followed by post-hatching vaccination with an anticoccidial vaccine and/or other vaccine. Alternatively, either method can be utilized without the subsequent vaccination step for stimulating non-specific cell-mediated immune responses in poultry.

Abstract: A recombinant herpes virus is provided which efficiently expresses an exogenous protein of interest in an inoculated animal host to thereby endow the host with excellent immunization. A recombinant herpes virus which incorporates an exogenous gene expression cassette in which a herpes virus-derived gB gene (a gene homologous to herpes simplex virus gB gene) promoter is used as a promoter for expression of an exogenous gene.

Abstract: The present invention provides NAD-independent Mycoplasma synoviae of strain MS1. The invention also refers to microbiological cultures comprising Mycoplasma synoviae of this strain. Next to this, the invention refers to live vaccines derived from these strains, for the protection of poultry against Mycoplasma synoviae infection. Furthermore, the invention provides methods for the preparation of such vaccines. Also, the use of NAD-independent Mycoplasma synoviae strains for the preparation of live vaccines for the protection of poultry against Mycoplasma synoviae infection is disclosed.

Abstract: The present invention provides a vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order which comprises an immunogenic amount of a modified live avian polyomavirus in a pharmaceutically acceptable carrier. Methods are also provided for preventing avian polyomavirus infection in a bird, or in several different species of birds, classified as being a member of the Psittaciformes order, comprising administering a vaccine comprising an immunogenic amount of a modified live avian polyomavirus and a pharmaceutically acceptable carrier. A preferred embodiment provides a modified live avian polyomavirus vaccine for prevention of wild-type infection in a Budgerigar, lovebird or Cockatiel.

Abstract: Novel sequences in the genome of a wild type isolate of chicken infectious anemia virus are described, The amino acid sequence of a polypeptide, VP1, encoded by a novel sequence is also disclosed. Additionally, disclosed are the unexpected properties of the isolate which are related to novel amino acids positioned in the amino acid sequence of this isolate's VP1, as compared to the sequence of VP1 found in cell culture-adapted strains; and use of the novel sequences and their respective polypeptides in strategies to control chicken infectious anemia such as by vaccination.

Abstract: Recombinant genetic information (DNA or RNA), comprising a Chicken Anemia Virus (CAV)-specific nucleotide sequence and the use thereof for diagnostics, vaccination or protein production. Recombinant CAV protein and the use thereof for diagnostics, vaccination or production of CAV-specific antibodies. The use of CAV-specific antibodies thus obtained.

Abstract: The present invention describes a reliably protective avian vaccine that contains a DNA transcription unit comprising a nucleic acid that encodes a viral protein. This effective and reliable avian vaccine significantly improves upon that which heretofore has been disclosed. The present invention demonstrates that the reliable efficacy found for DNA influenza vaccines, formerly observed in experimental inbred mice, can now be obtained for outbred avian species as well. Methods of use and specific DNA constructs are disclosed.

Abstract: The present invention is concerned with the preparation of improved inactivated vaccines, in particular of inactivated poultry vaccines. The immunogenicity of the inactivated immunogens in such vaccines is enhanced in case live CAV are administered in a combination vaccine with these inactivated immnogens.

Abstract: A method for preventing and treating parasitic infections in animals by administering a lysine analog, such as EACA, to the animals on a continuous basis. In the preferred embodiment, the method of the present invention is directed to preventing and treating coccidial infections in poultry by adding EACA to the daily diet of a poultry flock. EACA may also be administered in ovo before hatching. The administration of EACA enhances the natural immune response of the poultry to the invading coccidial organisms and enables the poultry to combat the parasites without the need for antibiotics. Another aspect of the present invention involves preventing parasitic diseases in humans and animals by prophylactically administering a serine protease inhibitor, such as EACA, as an adjuvant in conjunction with a conventional vaccine effective against the target parasite.

Abstract: The invention encompasses methods and compositions for inducing an immune response in an anti-Gal synthesizing animal including viral and tumor antigens manipulated to express .alpha.-galactosyl epitopes.

Abstract: A system for the generation of live Birnavirus such as infectious bursal disease virus (IBDV), a segmented double-stranded (ds)RNA virus of the Birnavirdae family, using synthetic transcripts derived from cloned DNA has been developed. Independent full-length cDNA clones were constructed which contained the entire coding and non-coding regions of RNA segments A and B of IBDV, respectively. Synthetic RNAs of both segments were produced by in vitro transcription of linearized plasmids with T7 RNA polymerase. Transfection of Vero cells with combined plus-sense transcripts of both segments generated infectious virus as early as 36 hours post-transfection. The development of a reverse genetics system for dsRNA viruses will greatly facilitate studies of the regulation of viral gene expression pathogenesis, and design of a new generation of live and inactivated vaccines.

Abstract: A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HAO), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The recombinant vaccine can be developed from primary sources of influenza, for example, nasal secretions from infected individuals, rather than from virus adapted to and cultured in chicken eggs. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. In the preferred embodiment, the cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide.

Abstract: The present invention provides a recombinant herpesvirus of turkeys designated S-HVT-050 (ATCC Accession No. VR 2400). A vaccine is provided which comprises an effective immunizing amount of S-HVT-050 and a suitable carrier. A method of immunizing a fowl against disease caused by Marek's disease virus and Newcastle disease virus is also provided which comprises administering to the fowl an effective immunizing dose of the vaccine of the present invention.

Abstract: Invention relates to a vaccine for the prevention of Infectious Bursal Disease in poultry comprising an effective immunizing amount of a live attenuated intermediately-pathogenic IBD virus belonging to the strain deposited at the ECACC under No. V92052301 (MB), an effective immunizing amount of a live attenuated intermediately-pathogenic IBD virus belonging to the strain deposited at the ECACC under No. V92100106 (MB-2), or an effective immunizing amount of a live attenuated intermediately-pathogenic IBD virus belonging to the strain deposited at the ECACC under No. V92102209 (MB-1).

Abstract: A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a trivalent influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HA0), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. The cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide. A general approach for the efficient extraction and purification of recombinant HA protein produced in insect cells is also disclosed which can be adapted for the purification of rHA proteins from A sub-types and B type influenza viruses.

Abstract: This invention relates to a novel infectious bronchitis virus (IBV) serotype and to attenuated IBV strains derived therefrom, and also to live or inactivated vaccines made using such IB virus.

Abstract: The present invention provides a combination vaccine for use in the protection of poultry against ND comprising an expression system, such as a virus vector, expressing a NDV immunogenic protein, and a live NDV vaccine strain. It is demonstrated that such a combination vaccine affords good local and systemic protection.

Abstract: The present invention provides a live and inactivated Chicken Anaemia Agent vaccine capable of evoking an immune response in a vaccinated chicken. The CAA virus of the vaccine is attenuated by serial passages in embryonated eggs.

Abstract: A novel nucleotide sequence in the genome of Marek's disease virus (MDV) containing an open reading frame, whose expression is associated with lytic infection and tumor cell development in MDV-infected cells, is described. Also described is the use of this novel sequence for molecular diagnostics of serotype 1 MDV; and to generate a recombinant MDV by inserting one or more endogenous or exogenous genes, operably linked to a control element for expression, into a region of the MDV genome comprising the novel nucleotide sequence, wherein the insertion interrupts expression of the open reading frame.

Abstract: The present invention provides a live and inactivated Chicken Anaemia Agent vaccine capable of evoking an immune response in a vaccinated chicken. The CAA virus of the vaccine is attenuated by serial passages in embryonated eggs.

Abstract: Herpesviruses naturally deficient in gD, that is to say not expressing their gD gene in vitro or not possessing this gene, are transformed to express gD in vitro. This transformation by genetic recombination can consist in replacement of the natural promoter by another one or insertion of an expression cassette containing gD and a promoter. The invention also relates to these viruses incorporating a gene coding for an antigen of interest, to the vaccines obtained and to the methods of culture thus improved. The invention relates in particular to avian herpesviruses, especially MDV, and the VZV virus.

Abstract: A method of producing infectious bursal disease virus comprising culturing infectious bursal disease virus in a mammalian cell line for two to ten days.

Abstract: A vaccine for Marek's disease using mutant strains of a serotype 2 field isolate, designated 471B/1, is disclosed. The mutant viruses, which are produced by serial passage of 471B/1 in cell culture, not only retain effective immunizing ability against Marek's disease virus, but which also exhibit reduced enhancement of lymphoid leukosis in comparison to non-passaged 471B/1 and conventional serotype 2 vaccines. These viruses or immunogenic components thereof can be formulated into monovalent and polyvalent vaccines.

Abstract: The present invention provides a vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order which comprises an immunogenic amount of an inactivated avian polyomavirus in a pharmaceutically acceptable carrier. Also provided is an adjuvant suitable for use in a bird which is classified as being a member of the Psittaciformes order. Further provided is a composition which produces an anamnestic response against avian polyomavirus infection in a sensitized bird which is classified as being a member of the Psittaciformes order, which comprises an anamnestic response inducing amount of a recombinant protein (e.g., VP1 capsid protein) of avian polyomavirus in a pharmaceutically acceptable carrier.

Abstract: A new virus not neutralized or bound by monoclonal antibodies which are group neutralizing to all IBDV vaccines of current art, and capable of inducing infectious bursal disease in poultry is identified, in essentially pure form. A test kit, and assay for the presence of the virus is disclosed, together with the vaccine incorporating the virus. A monoclonal antibody Mab 50, which neutralizes the virus, form the basis of an alternative vaccine.

Abstract: The present invention is concerned with a recombinant Herpesvirus of Turkeys (HVT), containing a heterologous gene incorporated into an insertion region of the genome of HVT. The invention also relates to a vector vaccine comprising such a recombinant HVT which expresses a heterologous antigenic polypeptide and induces an adequate immune response on infection of an appropriate host animal.

Abstract: An isolated nucleic acid molecule encoding the gB glycoprotein of Infectious Laryngotracheitis Virus is disclosed. Also disclosed is incorporation of the gB gene into recombinant avipox virus for a vaccine used to immunize fowl.

Abstract: This invention involves a chemically transformed chicken hepatocyte derived cell line which is capable of efficiently supporting replication of infectious laryngotracheitis virus (ILTV) and methods for cultivating ILTV using this hepatocellular carcinoma cell line. The virus harvested from these continuous cell culture methods can be used as a vaccine against ILTV infection.